Tim Cooke | CEO
Omniose

Tim Cooke, CEO, Omniose

Dr. Cooke has over thirty years of experience in the biopharmaceutical industry with a focus on vaccines.  He was previously CEO of NovaDigm Therapeutics, CEO of Mojave Therapeutics, COO at AVANT Immunotherapeutics, and SVP at Ology Bioservices. Prior to his leadership roles in the biotechnology industry, he held several positions at Merck establishing a global vaccine-focused marketing and sales organization. Dr. Cooke was the Biotechnology Industry Representative to the U.S. National Vaccine Advisory Committee during 2015-2023. He is on the Advisory Board of Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) and is an observer on the WHO Technical Advisory Group on Vaccines and Antimicrobial Resistance.  He was previously Co-Chair of the BIO Vaccine Policy Advisory Committee and was on the Incentives for Vaccines Working Group of the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria. Dr. Cooke was the Vaccine Industry Representative to the Working Group of Gavi, the Vaccine Alliance during its formation in 2000. Dr. Cooke has a Ph.D. in bio-organic chemistry and an M.B.A. from Columbia University and a B.S. from Saint Joseph’s University.

Appearances:



Day 2 - Wednesday 30th October @ 15:30

The Role of Vaccines & mAbs in Neonatal Sepsis Prevention

last published: 10/Jun/24 12:45 GMT

back to speakers